Vatiquinone
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mitochondrial Disease
Conditions
Mitochondrial Disease
Trial Timeline
— → —
NCT ID
NCT07159139About Vatiquinone
Vatiquinone is a pre-clinical stage product being developed by PTC Therapeutics for Mitochondrial Disease. The current trial status is active. This product is registered under clinical trial identifier NCT07159139. Target conditions include Mitochondrial Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07159139 | Pre-clinical | Active |
| NCT05515536 | Phase 3 | Active |
| NCT05485987 | Phase 2 | Completed |
| NCT05218655 | Phase 3 | Completed |
| NCT04378075 | Phase 2/3 | Terminated |
Competing Products
13 competing products in Mitochondrial Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| REN001 | OnKure Therapeutics | Phase 1 | 25 |
| Mavodelpar + Placebo | OnKure Therapeutics | Phase 2 | 44 |
| REN001 | OnKure Therapeutics | Phase 2/3 | 57 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 2 | 52 |
| Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mg | AbbVie | Phase 2 | 52 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Vatiquinone | PTC Therapeutics | Phase 2/3 | 62 |
| EPI-743 | PTC Therapeutics | Pre-clinical | 20 |
| RG2133 (2',3',5'-tri-O-acetyluridine) | Repligen | Phase 1 | 30 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 74 |
| Oral administration of 100 mg KH176 twice daily | Certara | Phase 2 | 47 |
| Sonlicromanol + Placebo | Certara | Phase 2 | 47 |